latest news releases from the newsroom
Powerwave Technologies Reports First Quarter Results
SANTA ANA, Calif., May 2, 2005 (PRIMEZONE) -- Powerwave Technologies, Inc. (Nasdaq:PWAV) today reported net sales of $162.2 million for its first quarter ended April 3, 2005, compared to first quarter fiscal 2004 revenues of $63.2 million. Powerwave also reported first quarter net income of $5.4 million, which includes a total of $3.9 million of acquisition related intangible asset amortization and a one-time charge of $0.4 million related to the allocation of a portion of the purchase price associated with Powerwave's acquisition of certain assets of Kaval Wireless to in-process research and development expenses. The net income equates to fully diluted earnings per share of 5 cents for the first quarter, and a basic earnings per share of 5 cents for the same period.
SmartPros' Subsidiary, Working Values, Ltd., Expands Network of Affiliated Ethics Services Providers With Orsborn Partners
HAWTHORNE, N.Y., May 2, 2005 (PRIMEZONE) -- Working Values,(r) Ltd., a wholly owned subsidiary of SmartPros Ltd. (AMEX:PED), a leading developer of accredited continuing professional education, today announced that Orsborn Partners, Inc. has agreed to join Working Values' proprietary national network of affiliated ethics services providers, comprised of globally recognized experts in the field of corporate ethics, compliance and reputation management.
EQT Sells Sirona to Madison Dearborn Partners, LLC
STOCKHOLM, Sweden, May 2, 2005 (PRIMEZONE) -- EQT III Limited ("EQT") together with Sirona management has signed an agreement with Madison Dearborn Partners, LLC to sell Sirona Group, a leading manufacturer of dental equipment for clinics and dental laboratories.
Pharming Group N.V.
Pharming Presents Phase II / III Clinical Results With Recombinant Human C1 Inhibitor
LEIDEN, Netherlands, May 2, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today clinical results from Phase II/III clinical studies with recombinant human C1 inhibitor ("rhC1INH") for the treatment of hereditary angioedema ("HAE"). The positive results were reported from the open label clinical studies being conducted in five European countries at the 4th C1-INH Deficiency Workshop in Budapest, Hungary.
Tomas Puusepp Assumes Position as President & CEO of Elekta -- New Managers Appointed For Global Sales and for Market Region Europe
STOCKHOLM, Sweden, May 1, 2005 (PRIMEZONE) -- (photo of Tomas Puusepp available for download, please see link at end of this text) Today, May 1, 2005, Tomas Puusepp assumes the position of President and CEO of Elekta, the international medical-technology group. Laurent Leksell, the company's largest shareholder and former President and CEO, instead assumes a new role, focusing on Group's strategic development, long-term customer relations and expansion into new markets.